Here are the overarching themes, latest programmatic additions to the Summit’s CEOs, policymakers and thought leaders convening this year as well as the security protocols to expect in Laguna.
Read MoreWhy two physicians-turned-investors are expecting the digital health market to level off in 2022 and how CEOs should navigate this burgeoning—and potentially tumultuous—market.
Read MoreFor nearly every sector of the health care world, M&A activity increased from 2020 to 2021 in both deal volume and value. Here are some of the major deals from Q4 across the payer, provider, life sciences and tech worlds.
Read MoreHealth Evolution SVP Rob Lazerow discusses what will be different at this year’s Summit, some of the CEO-centric themes that will be addressed and the points of inspiration CEOs will gain in Laguna.
Read MoreTwo giants of American business announced plans to divide themselves into smaller companies. What does it mean for the health care industry?
Read MoreIn health care—and across the Globe—M&A activity continued at a frenzy in the Summer months. Notable deals from the last three months included the mergers between Baxter and Hill-Rom, Intermountain Healthcare and SCL Health, Ginger and Headspace, and more.
Read MoreAt the Health Evolution Summit, federal and state policy leaders went into depth about what kind of impact increased M&A activity in health care might have on care coordination.
Read MoreThe in-person Summit is sold out, but virtual registrants can access all Main Stage programming featuring more than 30 CEOs leading large health systems, health plans and life sciences organizations as well as the Brass Tacks breakout discussions and networking opportunities with other Summit participants.
Read MoreFrom difficult conversations about racism and the experience of trauma to digital health funding to alternative and disruptive payment models, the first half of this year saw critical developments in executives thinking, practices and strategies.
Read MoreReviewing some of the major mergers and acquisitions that occurred from March to June, in general the spring months saw numerous high-value deals across the provider, life sciences and health tech sectors.
Read More